Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Iscience|August 9, 2021
Intercellular cGAMP transmission induces innate immune activation and tissue inflammation in Trex1 deficiencyBianca B Jütte, Calvin Krollmann, Kevin Cieslak, et al.
Elife|March 20, 2025
Tissue inflammation induced by constitutively active STING is mediated by enhanced TNF signalingHella Luksch, Felix Schulze, David Geißler-Lösch, et al.
Annals of Hematology|July 29, 2024
MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patientsStefanie Jilg, Juliana Schwaab, Katja Sockel, et al.
Nature Communications|November 26, 2025
NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasmsRuth-Miriam Koerber, Calvin Krollmann, Kevin Cieslak, et al.
EMBO Molecular Medicine|July 8, 2024
Platelet transcription factors license the pro-inflammatory cytokine response of human monocytesIbrahim Hawwari, Lukas Rossnagel, Nathalia Rosero, et al.
Annals of Hematology|August 17, 2023
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) StudySusanne Isfort, Kirsi Manz, Lino L Teichmann, et al.
The Journal of Experimental Medicine|August 23, 2022
Monocyte-derived macrophages aggravate pulmonary vasculitis via cGAS/STING/IFN-mediated nucleic acid sensingNina Kessler, Susanne F Viehmann, Calvin Krollmann, et al.
Leukemia|January 12, 2026
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)Andreas Burchert, Franck E Nicolini, Philipp le Coutre, et al.
Pageof 2